## SENATE BILL 13

J14lr1239 **CF HB 51** (PRE-FILED) By: Senator Jackson Requested: October 30, 2023 Introduced and read first time: January 10, 2024 Assigned to: Finance Committee Report: Favorable with amendments Senate action: Adopted Read second time: February 29, 2024 CHAPTER AN ACT concerning **Maryland Pediatric Cancer Fund - Modifications** Public Health - Maryland Pediatric Cancer Fund and Commission FOR the purpose of altering the use of the Marvland Pediatric Cancer Fund to require that the Fund be used only for pediatric cancer research instead of only for pediatric cancer research, prevention, and treatment; establishing the Pediatric Cancer Research Commission to oversee the award of competitive grants from the Fund; and generally relating to the Maryland Pediatric Cancer Fund and the Pediatric Cancer Research Commission. BY repealing and reenacting, with amendments, Article – Health – General Section 20–120 Annotated Code of Maryland (2023 Replacement Volume) BY adding to <u> Article – Health – General</u> Section 20–121 Annotated Code of Maryland (2023 Replacement Volume) SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:

## EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17 18

19


20

21

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



## Article - Health - General 1 2 20-120.3 In this section the following words have the meanings indicated. (a) (1) "Fund" means the Maryland Pediatric Cancer Fund established under 4 (2)5 this section. 6 "Pediatric cancer research" includes research to develop and advance (3)7 the understanding of pediatric cancer and the techniques and modalities effective in the prevention, cure, screening, and treatment of pediatric cancer. 8 9 (b) (1) There is a Maryland Pediatric Cancer Fund. 10 (2) The Fund consists of: 11 (i) Money appropriated in the State budget to the Fund; and 12 Any donations or other money from any other source accepted for (ii) 13 the benefit of the Fund. 14 (3)The Secretary shall administer the Fund. 15 **(4)** The Fund shall be used only for pediatric cancer research, prevention, and treatment as provided in subsection (c) of this section. 16 The Fund shall be maintained for the purposes stated in this section 17 18 and unspent portions of the Fund shall remain in the Fund and may not revert to the General Fund of the State. 19 Money expended from the Fund for pediatric cancer research[, 20 21prevention, and treatment is supplemental and is not intended to take the place of funding 22 that would otherwise be appropriated to the Department for pediatric cancer research. 23 prevention, and treatment]. 24All expenditures from the Fund shall be made only in accordance with 25an appropriation approved by the General Assembly in the annual State budget or through an approved budget amendment under §§ 7-209 and 7-210 of the State Finance and 2627 Procurement Article. 28 (8)(i) For fiscal year 2023, the Governor shall include in the annual 29 budget bill an appropriation of \$5,000,000 to the Fund.



THE PURPOSE OF THE COMMISSION IS TO OVERSEE THE AWARD OF

COMPETITIVE GRANTS FROM THE PEDIATRIC CANCER FUND, ESTABLISHED UNDER

§ 20–120 OF THIS SUBTITLE, TO PUBLIC AND PRIVATE ENTITIES IN THE STATE.

(D) THE COMMISSION CONSISTS OF:

30

31 32

33

**(C)** 

1 2	(1) THE SECRETARY OF HEALTH, OR THE SECRETARY'S DESIGNEE; AND
3	(2) THE FOLLOWING MEMBERS APPOINTED BY THE GOVERNOR:
4 5 6	(I) Two individuals who are adult survivors of Pediatric cancer or caregivers of Pediatric cancer patients, from a list submitted by the American Childhood Cancer Organization;
7 8	(II) ONE REPRESENTATIVE OF THE AMERICAN CHILDHOOD CANCER ORGANIZATION;
9 10	(III) TWO SCIENTISTS WITH EXPERTISE IN PEDIATRIC CANCER RESEARCH FROM THE UNIVERSITY OF MARYLAND;
11 12	(IV) TWO SCIENTISTS WITH EXPERTISE IN PEDIATRIC CANCER RESEARCH FROM JOHNS HOPKINS UNIVERSITY;
13 14	(V) TWO ADVANCED PRACTICE REGISTERED NURSES WHO HAVE EXPERIENCE IN PEDIATRIC CANCER CARE;
15 16	(VI) ONE PHYSICIAN WITH EXPERTISE IN TREATING PEDIATRIC CANCER PATIENTS FROM THE UNIVERSITY OF MARYLAND MEDICAL SYSTEM;
17 18	(VII) ONE PHYSICIAN WITH EXPERTISE IN TREATING PEDIATRIC CANCER PATIENTS FROM JOHNS HOPKINS MEDICINE;
19 20	(VIII) ONE PHYSICIAN WITH EXPERTISE IN PEDIATRIC ONCOLOGY FROM LIFEBRIDGE HEALTH; AND
21 22	(IX) ONE INDIVIDUAL WITH EXPERTISE IN PEDIATRIC ONCOLOGY FROM THE NATIONAL CANCER INSTITUTE.
23	(E) (1) THE TERM OF AN APPOINTED MEMBER IS 3 YEARS.
<ul><li>24</li><li>25</li><li>26</li></ul>	(2) The terms of the appointed members of the Commission are staggered as required by the terms provided for members of the Commission on October 1, 2024.
27 28 29	(3) If a vacancy occurs during the term of an appointed member, the Governor shall appoint a successor who shall serve until the term expires.

1	(4) AT THE END OF A TERM, A MEMBER MAY CONTINUE TO SERVE
2	ONLY UNTIL A SUCCESSOR IS APPOINTED AND QUALIFIES.
3	(5) A MEMBER WHO IS APPOINTED AFTER A TERM HAS BEGUN SERVES
4	ONLY FOR THE REST OF THE TERM AND UNTIL A SUCCESSOR IS APPOINTED AND
5	QUALIFIES.
6	(6) A MEMBER MAY NOT SERVE MORE THAN TWO CONSECUTIVE FULL
7	TERMS.
•	I DIVINO.
8	(F) EACH MEMBER OF THE COMMISSION SHALL DISCLOSE TO THE STATE
9	ETHICS COMMISSION WHETHER THE MEMBER IS EMPLOYED BY OR HAS A FINANCIAL
10	INTEREST IN AN ENTITY THAT MAY APPLY TO CONDUCT STATE-FUNDED PEDIATRIC
11	CANCER RESEARCH.
12	(G) (1) THE GOVERNOR MAY REMOVE A MEMBER FOR NEGLECT OF DUTY,
13	INCOMPETENCE, MISCONDUCT, MALFEASANCE, MISFEASANCE, NONFEASANCE, OR
14	ANY OTHER SUFFICIENT CAUSE.
15	(2) THE GOVERNOR MAY NOT REMOVE A MEMBER FOR POLITICAL
16	PARTY PREFERENCE.
10	TARTITREFERENCE.
17	(H) (1) A MAJORITY OF THE FULL AUTHORIZED MEMBERSHIP OF THE
18	COMMISSION IS A QUORUM.
19	(2) THE DECISION OF THE COMMISSION SHALL BE BY A MAJORITY OF
20	THE QUORUM PRESENT AND VOTING.
21	(I) THE COMMISSION SHALL MEET AT LEAST TWICE A YEAR, AT THE TIMES
22	AND PLACES THAT IT DETERMINES.
23	(J) A MEMBER OF THE COMMISSION:
20	(5) A MEMBER OF THE COMMISSION.
24	(1) MAY NOT RECEIVE COMPENSATION AS A MEMBER OF THE
25	COMMISSION; BUT
26	(2) IS ENTITLED TO REIMBURSEMENT FOR EXPENSES UNDER THE
27	STANDARD STATE TRAVEL REGULATIONS, AS PROVIDED IN THE STATE BUDGET.
28	(K) THE COMMISSION ANNUALLY SHALL ELECT A CHAIR AND VICE CHAIR

30 (L) THE COMMISSION SHALL:

FROM AMONG ITS MEMBERS.

29

1	(1) DEVELOP CRITERIA, STANDARDS, AND REQUIREMENTS FOR THE
2	REVIEW OF APPLICATIONS FOR PEDIATRIC CANCER RESEARCH GRANTS FROM THE
3	PEDIATRIC CANCER FUND;
4	(2) ESTABLISH PROCEDURES AND GUIDELINES TO BE USED IN THE
5	REVIEW, EVALUATION, RANKING, AND RATING OF THE RESEARCH GRANT
6	PROPOSALS;
_	
7	(3) REVIEW GRANT APPLICATIONS TO ENSURE THAT EACH
8	APPLICATION IS COMPLETE AND SATISFIES THE CRITERIA, STANDARDS, AND
9	REQUIREMENTS DEVELOPED BY THE COMMISSION UNDER ITEM (1) OF THIS
10	SUBSECTION;
11	(4) Develop pigglocupe and pegugal guidelines no de
12	(4) DEVELOP DISCLOSURE AND RECUSAL GUIDELINES TO BE
	FOLLOWED BY MEMBERS OF THE COMMISSION WHEN CONSIDERING GRANT
13	APPLICATIONS;
14	(5) ESTABLISH STANDARDS FOR THE OVERSIGHT OF AWARDS; AND
15	(6) CONDUCT PROGRESS REVIEWS OF GRANT RECIPIENTS.
16	(M) THE COMMISSION MAY CONSULT WITH EXPERTS IN PERFORMING ITS
17	DUTIES.
18	SECTION 2. AND BE IT FURTHER ENACTED, That the terms of the initial
19	members of the Pediatric Cancer Research Commission shall expire as follows:
00	(1) (1 1 1 200 )
20	(1)   four members in 2025;
21	(2) four members in 2026; and
41	(2) lour members in 2020, and
22	(3) five members in 2027.
_ <b>_</b>	72) ==- <u> </u>
23	SECTION 2. 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
24	October 1 2024